Iovance Biotherapeutics, Inc. (IOVA)
| Market Cap | 2.43B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -358.41M |
| Shares Out | 157.17M |
| EPS (ttm) | -2.30 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,478,173 |
| Open | 15.23 |
| Previous Close | 14.95 |
| Day's Range | 14.49 - 15.59 |
| 52-Week Range | 11.91 - 28.00 |
| Beta | 0.86 |
| Analysts | Buy |
| Price Target | 36.17 (+134.4%) |
| Earnings Date | May 5, 2022 |
About IOVA
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastat...
Financial Performance
Financial StatementsAnalyst Forecast
According to 20 analysts, the average rating for IOVA stock is "Buy." The 12-month stock price forecast is 36.17, which is an increase of 134.41% from the latest price.
News
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SAN CARLOS, Calif., May 20, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announce...
Iovance (IOVA) Q1 Earnings Beat, Lifileucel BLA on Track
Iovance Biotherapeutics (IOVA) reports a narrower-than-expected first-quarter loss. The company is on track to file a regulatory submission for lifileucel in melanoma in August 2022.
Iovance Biotherapeutics Reports First Quarter 2022 Financial Results and Corporate Updates
First Biologics License Application (BLA) Submission Planned in August 2022 First Biologics License Application (BLA) Submission Planned in August 2022
Iovance Biotherapeutics to Present Translational Data for Lifileucel in Advanced Melanoma at 2022 ASCO Annual Meeting
SAN CARLOS, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announ...
Iovance Biotherapeutics to Host First Quarter Financial Results Conference Call and Webcast on Thursday, May 5, 2022
SAN CARLOS, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report ...
Iovance Biotherapeutics to Present at Chardan Genetic Medicines and Cell Therapy Manufacturing Summit
SAN CARLOS, Calif., April 25, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announ...
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SAN CARLOS, Calif., April 22, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announ...
Iovance (IOVA) Stock Rallies 33% in a Month: Here's Why
Iovance (IOVA) to complete the FDA filing for its lead candidate in melanoma by August. It will start a clinical study for its first TALEN-edited TIL therapy for two advanced cancer indications later th...
Iovance (IOVA) to Seek FDA Nod for Melanoma Therapy in August
Iovance (IOVA) expects to complete FDA filing for lifileucel in metastatic melanoma by August 2022. It also intends to start a phase III combo study with lifileucel in melanoma in late 2022.
Iovance Biotherapeutics Announces Regulatory and Clinical Updates for Lifileucel in Melanoma
Positive FDA Feedback on Potency Assay Matrix to Support BLA Submission
Iovance (IOVA) to Start Clinical Studies for TIL Therapy
Iovance (IOVA) gets FDA nod to start clinical study for IOV-4001, which utilizes the technology licensed from Cellectis. A clinical study in melanoma or NSCLC indication is expected to begin in 2022.
Iovance Biotherapeutics to Present at Upcoming Conferences
SAN CARLOS, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announ...
Iovance Biotherapeutics' Investigational New Drug Application (IND) Allowed to Proceed for TALEN®-Edited Tumor Infilt...
Clinical Study Expected to Begin in 2022 to Investigate the Safety and Efficacy of IOV-4001 to Deliver TIL and PD-1 Inhibition within a Single Cancer Therapy
Iovance Biotherapeutics to Present at American Association for Cancer Research (AACR) 2022 Annual Meeting
SAN CARLOS, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announ...
Iovance (IOVA) Announces Wider-Than-Anticipated Q4 Loss
Iovance Biotherapeutics' (IOVA) fourth-quarter loss is wider than expected. The company is on track to file regulatory submission for lifileucel in melanoma by first-half 2022.
Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Updates
Expanding TIL Platform in Multiple Solid Tumors and Treatment Settings Expanding TIL Platform in Multiple Solid Tumors and Treatment Settings
Iovance Biotherapeutics to Host Fourth Quarter and Full Year Financial Results Conference Call and Webcast on Thursda...
SAN CARLOS, Calif., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report i...
Iovance Biotherapeutics Announces Raj K. Puri, M.D.
SAN CARLOS, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announc...
Iovance Biotherapeutics to Present Data on Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy at the 2022 Tandem Meetin...
TIL Therapy was Successfully and Consistently Manufactured from Cryopreserved Tumor Samples Shipped from Australia
Iovance Biotherapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022
SAN CARLOS, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announc...
Iovance's Lifileucel Combo Shows Encouraging Response Rates In Advanced Cancers
Iovance Biotherapeutics Inc (NASDAQ: IOVA) has announced data for lifileucel in combination with Merck Co Inc's (NYSE: MRK) Keytruda (pembrolizumab) in patients with advanced cancers. Data were presente...
Iovance Biotherapeutics Announces Clinical Data for Lifileucel in Combination with Pembrolizumab in Advanced Cancers ...
Tumor Infiltrating Lymphocyte (TIL) Cell Therapy in Combination with Pembrolizumab in Immune-Checkpoint Inhibitor Naïve Patients Shows Overall Response Rate (ORR) of 57% in Cervical Cancer, 60% in Melan...
Iovance Shares Tumble After Cell Therapy Data From Lung Cancer Trial
Iovance Biotherapeutics Inc (NASDAQ: IOVA) has announced additional data for LN-145 in patients with metastatic non-small cell lung cancer (mNSCLC) enrolled in Cohort 3B of the basket study IOV-COM-202....
Iovance Biotherapeutics Announces Clinical Data for LN-145 in Non-Small Cell Lung Cancer at Society for Immunotherapy...
21.4% Overall Response Rate (ORR) in Heavily Pre-Treated Patients with Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer (mNSCLC)